Market Overview

The Only Firm That Was Bearish On Chimerix Before The Selloff

The Only Firm That Was Bearish On Chimerix Before The Selloff
18 Stocks Which Rallied Four Days, Then Sold Off Yesterday
25 Stocks Which Rallied Three Days

Shares of Chimerix Inc (NASDAQ:CMRX) crashed on Monday. The stock fell more than 80 percent, from above $35 to under $7.50, after news that its brincidofovir SUPPRESS study has fallen short of endpoint expectations in the prevention of cytomegalovirus (CMV) infection.

Ahead of the crash, most Wall Street research firms were bullish on the company – and, of course, most of them became bearish after the tumble. However, one firm was bearish all along: Empire Asset Management.

Related Link: Here's What Wall Street Thinks Of Chimerix After The Crash

Before the selloff, Empire Asset Management was the only firm that rated Chimerix’s stock as a Sell case – with a $12 price target. The plummet in the stock price trumped the experts’ target, nonetheless. Consequently, they decided to terminate their coverage on the stock.

The Rationale

Management had been consistently providing information about its commercial preparation for a potential brincidofovir launch in the United States, the note explicated. Notwithstanding, the analysts believe that the negative data on SUPPRESS “will cause a suspension of most (if not all) of these activities.”

Moreover, the company had started some commercialization efforts for the E.U. and ROW as well, but, as they seemed preliminary, the experts also assume “these efforts will be significantly diminished.”

Having said this, however, the primary thesis behind Empire Asset Management’s Sell recommendation was “the competitive landscape and physician attitudes that brincidofovir would encounter if it gained marketing approval would be fierce and probably prevent it from reaching analysts’ lofty revenue estimates.” This trepidation was only increased by the bad news on SUPPRESS.

While the analysts recognized that brincidofovir could be potentially effective in other viral diseases like smallpox or adenovirus, they believe that “brincidofovir’s road to approval will be longer than most investors’ attention span and analysts’ estimates for potential brincidofovir revenues will be less attention grabbing.”

Disclosure: Javier Hasse holds no positions in any of the securities mentioned above.

Image Credit: Public Domain

Latest Ratings for CMRX

Feb 2016BarclaysDowngradesOverweightEqual-Weight
Feb 2016Morgan StanleyDowngradesEqual-WeightUnderweight
Feb 2016CitigroupDowngradesBuyNeutral

View More Analyst Ratings for CMRX
View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech Long Ideas Termination Health Care Top Stories Analyst Ratings Movers Best of Benzinga


Related Articles (CMRX)

View Comments and Join the Discussion!